Propanc Biopharma Inc (PPCB)
Propanc Biopharma Inc. is a development-stage biopharmaceutical company listed on NASDAQ under the ticker PPCB. Based in Camberwell, Australia, the company is focused on research and development of cancer treatments for pancreatic, ovarian, and colorectal cancers. Its lead candidate, PRP, is an intravenous proenzyme therapy that has completed pre-clinical studies and is being evaluated as a potential approach for cancer treatment and prevention. The company also maintains research collaborations with the University of Jaén for work on the POP1 Program and with the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma was incorporated in 2007 and operated under the name Propanc Health Group Corporation before adopting its current name in April 2017.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PPCB
|
$0.69
|
6.1% Upside
|
Fair
|
Not available
|
Not available
|
0.0%
|
October 1, 2026
|
0.2x
|
1.483 M
|
2.613 M
|
19.1%
|
55.8%
|
-32.0
|
21.7%
|
